2. Disease Activity Measures
3. Disease Outcome
4. Quality of Life and Economic Aspects
1. Overview of the Pathogenesis of SLE
4. Immunoregulation – T Cells, B cells, and cytokines.
5. Cell Surface Receptors ostimulation/BAFF/FcgR/TLRs)
6. Dendritic Cells
8. Structure and Origin of Autoantibodies
9. Animal Models
10. Genetics of murine lupus
11. Infection and autoimmunity
Mechanisms of Tissue Damage
2. Immune complexes
a. ANA and standardization of antibody techniques
c. Anti-splicesomosal ab
5. Mechanisms of renal damage
6. Mechanisms of vascular damage
7. Nitric Oxide
Clinical Aspects of the Disease
1. Constitutional Symptoms and Fatigue
8. Blood (anti-phospholipid syndrome)
9. Nervous System
10. Overlap Syndromes
11. Ophthalmic Manifestations
14. Neo-natal lupus
15. Hereditary and Malignant Lupus-like Diseases
Treatment of the Disease
1. Non-Steroidals – Anti-Malarials and Statins
2. Steroid Treatment
3. Cytotoxic Drug Treatment including M.M.F
5. New Treatments
This new companion to Hochberg et al.'s Rheumatology masterwork provides new insights into the causes, detection and therapy of this challenging disease. In this state-of-the-art resource, you'll find ‘one stop' coverage of all the latest scientific and clinical developments in SLE: new concepts in epidemiology, disease activity measures and outcomes; new concepts in immunoregulation, genetic and pathogenic mechanisms; new understanding and novel presentation of the processes of tissue/organ damage; comprehensive coverage of clinical features; and the very latest concepts in treatment.
- Provides the very latest understanding of the pathogenesis of SLE.
- Distills current understanding of the cellular, molecular, genetic and environmental factors that instigate and drive the disease.
- Includes comprehensive coverage of clinical features, including fatigue, organ system manifestations, overlap syndromes, infections, and more.
- Conveys the very latest understanding of mechanisms of tissue damage, including immune complexes, antibodies, and other mechanisms that lead to organ damage.
- Contains expert discussion of processes that are responsible for tissue injury - a hallmark of this text.
- Incorporates the latest treatment modalities, including steroids and non-steroidals, cytotoxic drug treatment, PAP's, and therapies on the horizon.
- Discusses the latest treatment options on disease modifying or disease controlling agents.
- No. of pages:
- © Mosby 2007
- 18th January 2007
- eBook ISBN:
- Hardcover ISBN:
After receiving an MD from University of Athens, he came to the Arthritis Branch in 1979 where he trained in immunology and rheumatology. Between 1987 and 2007 he was a member of the Uniformed Services/Walter Reed community where served in various positions including Vice Chair for Research in the Department of Medicine and Chief of the Department of Cell Injury. In 2007 he joined the Beth Israel Medical Center as Chief of Rheumatology and Harvard Medical School as Professor of Medicine. He has served various leadership positions including President of the Clinical Immunology Society. He has served as chair of the Hypersensitivity, Autoimmunity, and Immune Mediated Diseases Study Section of the National Institutes of Health, Editor-in-Chief of Clinical Immunology, the official journal of FOCIS, and editor of Autoimmunity and Discovery Medicine, PLoS One and other journals. He has been elected to the Association of American Physicians, Fellow of the American Association for the Advancement of Sciences and Master of the American College of Physicians (MACP). He is the 2012 Lee C. Howley Jr. Arthritis Research Prize from the Arthritis Foundation and a MERIT award holder from NIH. Dr. Tsokos’ research focuses on the cellular and molecular pathogenesis of systemic lupus erythematosus (SLE). His laboratory has opened and led the field of molecular abnormalities on immune cells in patients with SLE. He directs a T32-sponsored fellowship on systemic autoimmunity and a Clinical Rheumatology Fellowship. Dr. Tsokos has trained over 110 colleagues many of whom hold senior leadership positions and run independent laboratories. His research is funded through NIH and DoD grants.
Professor of Medicine, Harvard Medical School, and Chief, Rheumatology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA
Professor of Medicine, Chariman, Department of Medicine III, Division of Rheumatology, Medical University of Vienna;Chariman, Second Department of Medicine, Center for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria